← All indications
Microsatellite Instability
The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.
Drugs by status
Phase 3 trials (11)
Phase 2 trials (33)
- atezolizumab
- autologous tumor infiltrating lymphocytes
- bifidobacterium animalis
- irinotecan
- dpx-survivac
- durvalumab
- lapatinib
- pembrolizumab
- lenvatinib
- monalizumab
- niraparib
- regorafenib
- panitumumab
- ipilimumab
- rintatolimod
- cyclophosphamide
- temozolomide
- tremelimumab
- human fecal microbiota
- gimeracil
- oteracil
- fludarabine
- camrelizumab
- ibi310
- nogapendekin alfa inbakicept
- bintrafusp alfa
- leronlimab
- rp1
- cadonilimab
- nc410
- +3 more
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (22)
- Incyte
- Merck Serono
- ImmunoVaccine Technologies, Inc.
- Innovent Biologics (Suzhou) Co. Ltd.
- Nanobiotix
- National Cancer Institute (NCI)
- National Cancer Institute, France
- University of Pittsburgh
- University of Washington
- Johns Hopkins University
- UNICANCER
- Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- University of Colorado, Denver
- Institut Gustave Roussy
- University of Texas at Houston
- Altor Bioscience
- Ligue contre le cancer, France
- IFOM
- Hôpital Saint Antoine - PARIS
- Replimune Inc.
- Cancer League of Colorado, Inc
- Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano
Organization Involved with Phase 1 Indications (10)